Alizyme Therapeutics Limited Company Profile

12:13 EDT 17th March 2018 | BioPortfolio

Alizyme is a drug development company. It develops new products to treat diseases with high unmet medical need and substantial market opportunity. To date it has focussed on obesity and related diseases, such as diabetes, and on gastrointestinal disorders including irritable bowel syndrome, inflammatory bowel disease and mucositis, a serious side effect of cancer therapy.

Alizyme takes drug product candidates from an early stage into clinical development with the objective of demonstrating their efficacy in patients and providing a comprehensive data package to support the further development and commercialisation of the drug. Alizyme owns the intellectual property rights to all four drug products currently in clinical trials and has an exclusive worldwide licence to the COLAL™ drug delivery system.

At a suitable stage Alizyme aims to license its products to pharmaceutical companies that have the ability to complete the clinical development of the product, to gain approval from the regulatory authorities and to successfully market the product.

Alizyme has developed its business with a high emphasis on outsourcing, controlled by its core management team and specialist advisors. Rather than establish its own laboratories and development facilities, it has worked with collaborators and service providers such as contract research organisations. This has the benefit of allowing Alizyme to focus its investment onto its development programmes in a cost effective way.


Granta Park, Great Abingdon
United Kingdom


Phone: 44 1223 896000
Fax: 44 1223 896001

News Articles [792 Associated News Articles listed on BioPortfolio]

Appointment of Director

Oxford, UK, 1 November 2017: e-Therapeutics plc (AIM: ETX), a company pioneering the use of Network-Driven Drug Discovery (NDD) to create new and better drugs, announces the appointment of Christine...

Global Veterinary Therapeutics Market to Mark CAGR of 6.0% Over Next 10 Years - announces publication of its recently generated research report titled, "GlobalVeterinary Therapeutics MarketBy Type (Therapeutics Drugs, Therapeutics Vaccines, Feed Additives The...

What You Need to Know About Indalo Therapeutics

Indalo Therapeutics is based in St. Louis and was formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics.

Technical Perspectives on Argos Therapeutics, Omeros, Regulus Therapeutics, and Rhythm Pharma

Argos Therapeutics Durham, North Carolinaheadquartered Argos Therapeutics Inc.'s stock finished last Friday's session 3.20% higher at $0.15. A total volume of 1.81 million Read more...

Capricor Therapeutics to Present at the Piper Jaffray Healthcare Conference

About Capricor Therapeutics Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biolog...

Anika Therapeutics (ANIK) versus Onconova Therapeutics (ONTX) Financial Survey

Anika Therapeutics and Onconova Therapeutics are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earn...

What You Need to Know About DMD Therapeutics

DMD Therapeutics is based in Seattle, although at present it is a virtual company, and, as its name suggests, is focused on developing therapeutics for DMD.

Deals this week: Odonate Therapeutics, China Reform Holdings, Denali Therapeutics

US-based therapeutics developer Odonate Therapeutics LLC plans to raise $182.57m through an initial public offering (IPO) of 6,762,000 shares of...Read More... The post Deals this week: Odonate Therap...

PubMed Articles [405 Associated PubMed Articles listed on BioPortfolio]

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Introduction to Volume 1 of JOPT Special Issue.

Introduction to Volume 2 of JOPT Special Issue.

Eyes on New Product Development: Preclinical Research.

Clinical Trials [134 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1281 Associated Companies listed on BioPortfolio]

Alizyme Therapeutics Limited

Alizyme is a drug development company. It develops new products to treat diseases with high unmet medical need and substantial market opportunity. To date it has focussed on obesity and related diseas...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...

Alizyme plc

Alizyme is a speciality biopharmaceutical development company, based in Cambridge, UK. We are focused on developing products for the treatment and management of gastrointestinal disorders involving in...

Millendo Therapeutics, Inc.

Millendo Therapeutics is focused on developing a portfolio of disease-modifying treatments for endocrine diseases caused by hormone dysregulation. Our product candidates seek to i...

Circadian Technologies Limited

Circadian Technologies Limited is an emerging leader in the field of angiogenesis-based treatments for cancer. Focusing on a class of drug targets called Vascular Endothelial Growth Factors (VEGFs),...

More Information about "Alizyme Therapeutics Limited" on BioPortfolio

We have published hundreds of Alizyme Therapeutics Limited news stories on BioPortfolio along with dozens of Alizyme Therapeutics Limited Clinical Trials and PubMed Articles about Alizyme Therapeutics Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alizyme Therapeutics Limited Companies in our database. You can also find out about relevant Alizyme Therapeutics Limited Drugs and Medications on this site too.

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Obesity is the condition in which excess fat has accumulated in the body (mostly in subcutaneous tissues). clinical obesity is considered to be present when a person has a BMI of over 30 (Oxford Dictionary of Medicine). It is becoming increasing common i...

Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...

Corporate Database Quicklinks

Searches Linking to this Company Record